International Clinical and Medical Case Reports Journal (ISSN: 2832-5788) | Volume 4, Issue 8 | Case Report | Open Access
Houhong Wang*
Department of General Surgery, The Affiliated Bozhou Hospital of Anhui Medical University, China
*Correspondence to: Houhong Wang
Fulltext PDFReceptor Tyrosine Kinases (RTKs) are key regulators of cellular signaling pathways involved in proliferation, survival, and angiogenesis, and their dysregulation is a hallmark of Gastric Cancer (GC). This retrospective study systematically evaluated the expression profiles, clinical associations, and prognostic significance of major RTK families in GC using data from the PubMed database. We analyzed 52 eligible studies published between 2016 and 2024, involving 9,478 patients. Results showed that EGFR (42.6%, 95% CI: 38.1%-47.1%), HER2 (18.9%, 95% CI: 16.2%-21.6%), MET (37.8%, 95% CI: 33.5%-42.1%), and VEGFR2 (45.3%, 95% CI: 40.8%-49.8%) were the most frequently overexpressed RTKs. Overexpression of EGFR (OR = 2.89, 95% CI: 2.41-3.47, P < 0.001), HER2 (OR = 2.56, 95% CI: 2.15-3.04, P < 0.001), MET (OR = 3.12, 95% CI: 2.61-3.73, P < 0.001), and VEGFR2 (OR = 3.35, 95% CI: 2.82-3.97, P < 0.001) was significantly associated with advanced TNM stage. MET overexpression (HR = 2.27, 95% CI: 1.93-2.67, P < 0.001) and VEGFR2 overexpression (HR = 2.31, 95% CI: 1.96-2.72, P < 0.001) were the strongest predictors of poor Overall Survival (OS). In patients receiving RTK inhibitors, HER2-positive cases showed the highest objective response rate (46.8% vs. 19.2%, OR = 3.62, 95% CI: 2.87-4.56, P < 0.001). These findings highlight the clinical relevance of RTKs in GC and their potential as therapeutic targets.
Houhong Wang. Analysis of Receptor Tyrosine Kinases (RTKs) in Gastric Cancer. Int Clinc Med Case Rep Jour. 2025;4(8):1-3.